Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, vol.31, no.6, pp.645-648, 2006 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 31 Issue: 6
- Publication Date: 2006
- Doi Number: 10.1111/j.1365-2710.2006.00779.x
- Journal Name: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.645-648
- Keywords: ankylosing spondylitis, anti-tumour necrosis factor-alpha drugs, transverse myelitis, MULTIPLE-SCLEROSIS PATIENTS, ACUTE TRANSVERSE MYELITIS, NECROSIS, THERAPY, ASSOCIATION, FEATURES
- Akdeniz University Affiliated: Yes
Abstract
Anti-tumour necrosis factor (TNF)-alpha agents promise better disease control for treatment of inflammatory arthritides which are resistant to classical disease-modifying treatment and provide better functional outcome. But these agents are not free of adverse events. The exact relationship between use of anti-TNF drugs and development of demyelination cannot be established yet. Here we present a case of a 36-year-old man who developed demyelination in the cervical spinal cord while he was being treated with etanercept for ankylosing spondylitis.